NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
VA Office of Research and Development
Chinese University of Hong Kong
Uppsala University Hospital
Hospital Universitario La Fe